UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_18551/2024

PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF

Einstweilige MaßnahmenEinstweilige MaßnahmenDusseldorf LDApplication for provisional measures—
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Parteien

Kläger

  • Novartis AG
  • Genentech, Inc.
Vertreter: Frank-Erich Hufnagel (Freshfields Bruckhaus Deringer); Kilian Seidel (Freshfields Bruckhaus Deringer); Cameron Marshall (Carpmaels & Ransford LLP); Joanna Rowley (Carpmaels & Ransford LLP)

Beklagte

  • Celltrion Inc.
Richter
  • ThomasPresiding Judge
  • ThomLegally Qualified Judge
  • ZanaLegally Qualified Judge
  • PetersonTechnically Qualified Judge
Patente
  • EP 3 805 248
CPC-Codes: B01D2311/04, A61K39/39591, B01D2311/16, B01D61/146, C07K16/065, C07K2317/21, C07K16/4291, C07K1/34, B01D61/16

Sektor: Organic Chemistry

Ausgang
PI abgelehnt
Eingereicht: —
Erste Entscheidung: 6. Sept. 2024
Sprache: —

Order by Düsseldorf Local Division (UPC_CFI_166/2024, 6 September 2024) rejecting Novartis AG and Genentech Inc.'s application for provisional measures against Celltrion Inc. for alleged infringement of EP 3 805 248 B1 (biologic/antibody). The application was dismissed on the merits (infringement insufficiently established). Applicants were ordered to pay interim costs of EUR 138,562.80. The court addressed claim interpretation, imminent infringement, non-applicability of stay of proceedings (R. 295 RoP) to PI proceedings, and the costs gap in the absence of main proceedings.